Anticorps Recombinant de lapin anti-SARS-CoV-2 Spike
SARS-CoV-2 Spike Recombinant Antibody for ELISA
Hôte / Isotype
Human / IgG1
Réactivité testée
Virus
Applications
, ELISA
Conjugaison
Non conjugué
CloneNo.
AM032414
N° de cat : 91359-PTG
Synonymes
Galerie de données de validation
Applications testées
Résultats positifs en ELISA | Domaine RBD de la protéine Spike du SARS-CoV-2 |
Dilution recommandée
Application | Dilution |
---|---|
Sample dependent. To be determined by the end user. |
Remarque: Proteintech is partnering with Active Motif to bring these cutting-edge, patient derived antibodies to our customers during this important time for COVID-19 research.
Informations sur le produit
91359-PTG cible SARS-CoV-2 Spike dans les applications de , ELISA et montre une réactivité avec des échantillons Virus
Réactivité | Virus |
Hôte / Isotype | Human / IgG1 |
Clonalité | Recombinant |
Type | Anticorps |
Immunogène | Virus |
Nom complet | SARS-CoV-2 Spike Protein |
Masse moléculaire calculée | 141 kDa |
Numéro d’acquisition GenBank | NC_045512 |
Symbole du gène | COVID-19 S Protein |
Identification du gène (NCBI) | 43740568 |
Conjugaison | Non conjugué |
Forme | Liquide |
Méthode de purification | Chromatographie par protéine A |
Tampon de stockage | Hepes 140 mM, pH 7,5, NaCl 70 mM, NaOAc 32 mM, azoture de sodium à 0,035 % et glycérol à 30 %. |
Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
COVID-19, which is short for coronavirus disease 2019, is the official name of the respiratory disease caused by infection with the novel coronavirus SARS-CoV-2. The virus that causes COVID-19 was named SARS-CoV-2 because it is a coronavirus genetically similar to, yet distinct from, the virus that caused the severe acute respiratory syndrome (SARS) outbreak in 2003. Studying the details of how this virus replicates and causes the disease will allow scientists and physicians to more rapidly develop fast and accurate methods of detection as well as to deploy therapeutic and vaccine strategies. This antibody was derived from COVID-19 patients who have cleared the virus. Patient serum IgG was sequenced and expressed as full-length IgG1 with human immunoglobulin heavy and light chains in mammalian 293 cells.